Request Free Sample ×
UK Thyroid Disorder Market Infographic

Kindly complete the form below to receive a free sample of this Report

* Please use a valid business email

Leading companies partner with us for data-driven Insights

clients tt-cursor
Hero Background

UK Thyroid Disorder Market

ID: MRFR/HC/55235-HCR
200 Pages
Satyendra Maurya
March 2026

UK Thyroid Disorder Market Research Report: Size, Share, Trend Analysis By Types (Hypothyroidism, Hyperthyroidism), By Treatment (Medications, Radioactive Iodine Therapy, Surgery), By Route of Administration (Oral, Intravenous, others) and By End Users (Hospitals, Clinics, others) - Growth Outlook & Industry Forecast 2025 To 2035

Share:
Download PDF ×

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

UK Thyroid Disorder Market Infographic
Purchase Options
Compare License
Summary Table of Contents Segmentation Download PDF

UK Thyroid Disorder Market Summary

As per Market Research Future analysis, the UK thyroid disorder market size was estimated at 156.95 USD Million in 2024. The UK thyroid disorder market is projected to grow from 163.6 USD Million in 2025 to 247.92 USD Million by 2035, exhibiting a compound annual growth rate (CAGR) of 4.2% during the forecast period 2025 - 2035

Key Market Trends & Highlights

The UK thyroid disorder market is experiencing notable growth driven by increased awareness and advancements in treatment options.

  • Rising awareness and diagnosis of thyroid disorders are leading to earlier detection and improved patient outcomes.
  • Advancements in treatment options, including personalized medicine, are enhancing therapeutic efficacy and patient satisfaction.
  • Telemedicine integration is transforming patient access to care, particularly in remote areas, thereby expanding the market reach.
  • The increasing prevalence of thyroid disorders and innovations in diagnostic technologies are key drivers propelling market growth.

Market Size & Forecast

2024 Market Size 156.95 (USD Million)
2035 Market Size 247.92 (USD Million)
CAGR (2025 - 2035) 4.24%

Major Players

AbbVie (US), Bristol-Myers Squibb (US), Eli Lilly and Company (US), Merck & Co. (US), Novartis (CH), Pfizer (US), Sanofi (FR), Takeda Pharmaceutical Company (JP), Amgen (US)

Our Impact
Enabled $4.3B Revenue Impact for Fortune 500 and Leading Multinationals
Partnering with 2000+ Global Organizations Each Year
30K+ Citations by Top-Tier Firms in the Industry

UK Thyroid Disorder Market Trends

The thyroid disorder market is currently experiencing notable developments, driven by an increasing awareness of thyroid-related health issues among the population. This heightened awareness is leading to more individuals seeking diagnosis and treatment for conditions such as hypothyroidism and hyperthyroidism. Additionally, advancements in diagnostic technologies are facilitating earlier detection, which is crucial for effective management of these disorders. The integration of telemedicine is also transforming patient access to healthcare services, allowing for remote consultations and follow-ups, which is particularly beneficial for those in rural areas. Moreover, the thyroid disorder market is witnessing a rise in the demand for personalized medicine. Patients are increasingly looking for tailored treatment options that consider their unique genetic profiles and health conditions. This shift towards individualized care is prompting pharmaceutical companies to invest in research and development of targeted therapies. As a result, the market is likely to evolve, with a focus on innovative solutions that enhance patient outcomes and improve quality of life. Overall, the thyroid disorder market appears to be on a progressive trajectory, characterized by technological advancements and a patient-centric approach.

Rising Awareness and Diagnosis

There is a growing recognition of thyroid disorders among the general public, leading to increased screening and diagnosis. This trend is supported by public health campaigns that aim to educate individuals about the symptoms and risks associated with thyroid conditions.

Advancements in Treatment Options

The thyroid disorder market is seeing a surge in innovative treatment modalities, including biologics and targeted therapies. These advancements are designed to provide more effective management of thyroid disorders, catering to the specific needs of patients.

Telemedicine Integration

The incorporation of telemedicine into healthcare services is reshaping how patients access treatment for thyroid disorders. Remote consultations and digital health tools are enhancing patient engagement and facilitating ongoing management of their conditions.

UK Thyroid Disorder Market Drivers

Rising Healthcare Expenditure

The increasing healthcare expenditure in the UK is contributing to the growth of the thyroid disorder market. As the government allocates more funds towards healthcare services, there is a corresponding rise in the availability of resources for the diagnosis and treatment of thyroid disorders. This trend is likely to enhance patient access to necessary medical interventions, thereby driving market growth. The thyroid disorder market is poised to benefit from this increase in spending, as it may lead to the development of new therapies and improved healthcare infrastructure, ultimately enhancing patient outcomes.

Government Initiatives and Support

Government initiatives aimed at improving healthcare access and quality are significantly influencing the thyroid disorder market. In the UK, various health policies are being implemented to enhance screening programs and promote awareness of thyroid disorders. These initiatives are expected to lead to increased diagnosis rates and, consequently, a higher demand for treatment options. The thyroid disorder market is likely to see a positive impact from these government efforts, as they may facilitate funding for research and development, ultimately leading to improved therapies and patient care.

Innovations in Diagnostic Technologies

Advancements in diagnostic technologies are playing a crucial role in the thyroid disorder market. The introduction of more accurate and efficient testing methods, such as high-sensitivity thyroid-stimulating hormone (TSH) assays, is facilitating earlier detection of thyroid disorders. This is particularly relevant in the UK, where timely diagnosis can lead to better patient outcomes. The thyroid disorder market is likely to benefit from these innovations, as healthcare providers increasingly adopt new technologies to enhance patient care. Furthermore, the integration of artificial intelligence in diagnostic processes may streamline operations and reduce costs, potentially increasing market growth.

Growing Demand for Personalized Medicine

The shift towards personalized medicine is emerging as a key driver in the thyroid disorder market. Patients are increasingly seeking tailored treatment options that consider their unique genetic and biochemical profiles. This trend is particularly relevant in the UK, where healthcare providers are beginning to adopt more individualized approaches to treatment. The thyroid disorder market is likely to evolve in response to this demand, with pharmaceutical companies focusing on developing targeted therapies that enhance efficacy and minimize side effects. As personalized medicine gains traction, it may reshape treatment paradigms and improve patient satisfaction.

Increasing Prevalence of Thyroid Disorders

The thyroid disorder market is experiencing growth due to the rising prevalence of thyroid-related conditions in the UK. Recent data indicates that approximately 1 in 20 individuals may be affected by thyroid disorders, with women being disproportionately impacted. This increasing incidence is likely to drive demand for diagnostic tests and treatment options, thereby expanding the market. The thyroid disorder market is responding to this trend by enhancing awareness campaigns and improving access to healthcare services. As more individuals seek diagnosis and treatment, the market is expected to witness a significant uptick in both the number of patients and the associated healthcare expenditures.

Market Segment Insights

By Type: Hypothyroidism (Largest) vs. Hyperthyroidism (Fastest-Growing)

The UK thyroid disorder market is characterized by a significant share of hypothyroidism, which dominates the segment with a substantial portion of the market. This category includes patients who are mostly diagnosed with an underactive thyroid, leading to various health issues if left untreated. In contrast, hyperthyroidism, while smaller in market share, is rapidly gaining traction and is recognized for its increasing prevalence among the population. Growth trends within this segment are primarily driven by heightened awareness of thyroid-related disorders and advancements in diagnostic technologies. The rise in healthcare access has facilitated earlier diagnosis and treatment, which is crucial for managing both hypothyroidism and hyperthyroidism effectively. Additionally, the development of new therapies and public health campaigns focusing on thyroid health are boosting the growth of the hyperthyroidism segment, marking it as an area to watch in the coming years.

Hypothyroidism: Dominant vs. Hyperthyroidism: Emerging

Hypothyroidism represents the dominant force in the UK thyroid disorder market, characterized by a significant patient base who require ongoing management to maintain their health. This condition is often associated with symptoms such as fatigue, weight gain, and sensitivity to cold, necessitating consistent treatment and monitoring. In contrast, hyperthyroidism, though emerging, is gaining attention due to its potential for serious health complications like heart problems if untreated. The increasing incidence of hyperthyroidism among younger populations highlights an evolving dynamic within the market. With advances in treatment protocols and a growing emphasis on patient education, both segments are crucial for healthcare providers and stakeholders in delivering comprehensive thyroid health solutions.

By Treatment: Medications (Largest) vs. Radioactive iodine therapy (Fastest-Growing)

The UK thyroid disorder market's treatment segment is dominated by medications, capturing a significant market share compared to other treatment options. Medications are widely prescribed for managing hypothyroidism and hyperthyroidism, making them the preferred choice among healthcare providers. In contrast, while surgeries and radioactive iodine therapy contribute to the overall market, they hold smaller shares, emphasizing the reliance on pharmacological interventions in treatment plans. Growth trends indicate a robust increase in the demand for radioactive iodine therapy, which is quickly becoming a preferred method for treating specific thyroid conditions. This shift is driven by advancements in medical technology, increasing awareness of thyroid disorders, and the effectiveness of this treatment. Moreover, medications continue to evolve with new formulations and better patient adherence, sustaining their market presence.

Medications (Dominant) vs. Radioactive iodine therapy (Emerging)

Medications for thyroid disorders, primarily levothyroxine for hypothyroidism and antithyroid drugs for hyperthyroidism, continue to dominate the treatment landscape in the UK thyroid disorder market. Their widespread use is attributed to their effectiveness, ease of administration, and the increasing prevalence of thyroid disorders. In contrast, radioactive iodine therapy, while considered an emerging treatment option, is gaining traction due to its minimally invasive nature and high success rates for certain thyroid conditions. As more patients seek alternatives to traditional medication regimens, the adoption of radioactive iodine therapy is expected to rise, positioning it as a significant player in the evolving treatment paradigm.

By Route of Administration: Oral (Largest) vs. Intravenous (Fastest-Growing)

In the UK thyroid disorder market, the route of administration is split primarily between oral and intravenous methods. Oral administration dominates the market, accounting for a significant proportion of the overall usage due to its convenience and ease of adherence for patients. Intravenous administration, while smaller in share, is gaining traction, particularly in acute care settings where immediate action is required. Other routes, though present, play a minor role in the overall segment distribution. The growth trends within the route of administration segment highlight a notable shift towards intravenous solutions as healthcare providers focus on rapid treatment modalities for thyroid-related emergencies. The oral segment continues to thrive as advancements in formulations enhance patient compliance. Factors driving these changes include the rising prevalence of thyroid disorders and ongoing innovations in drug delivery technologies, promoting both segments' relevance in active treatment strategies.

Administration: Oral (Dominant) vs. Intravenous (Emerging)

The oral route of administration remains dominant in the UK thyroid disorder market due to its established history and patient-friendly characteristics. Patients often prefer oral formulations, which simplify daily regimens compared to intravenous alternatives that require professional administration. However, intravenous methods are quickly emerging as a viable option, particularly for patients with severe symptoms or those requiring rapid intervention. The efficacy of intravenous administration in providing immediate therapeutic impact makes it an attractive alternative, especially when timely management is critical. As healthcare evolves, the balance between these two routes will shape the future landscape of treatment for thyroid disorders, with both methods finding their niche based on clinical requirements and patient preferences.

By End-User: Clinics (Largest) vs. Hospitals (Fastest-Growing)

In the UK thyroid disorder market, Clinics command the largest market share, serving a significant number of patients with thyroid conditions. These facilities are pivotal in providing specialized care and follow-up services, enhancing patient accessibility and healthcare outcomes. In contrast, Hospitals are increasingly capturing market share and are recognized as the fastest-growing segment, driven by advancements in surgical techniques and increasing patient referrals for complex cases. The growth of the Hospital segment is mainly attributed to an overall rise in awareness and diagnosis of thyroid disorders, leading to increased admissions and treatment options. With the integration of innovative technology in treatment methodologies, Hospitals are adapting quickly to meet patient needs. Public and private investments are further fueling this growth by expanding facilities and resources to accommodate the rising patient volume in the sector.

Clinics (Dominant) vs. Hospitals (Emerging)

Clinics play a dominant role in the UK thyroid disorder market, primarily due to their focus on outpatient care and ongoing management of thyroid conditions. They facilitate a more personalized approach to treatment, often leading to higher patient satisfaction and adherence to treatment plans. This segment caters effectively to routine check-ups, thyroid function tests, and medication management, ensuring continuous care for patients. Conversely, Hospitals represent an emerging segment with a growing influence in the market. They provide comprehensive diagnostic and surgical services for complicated cases of thyroid disorders, thus attracting patients who require specialized care. The presence of multi-disciplinary teams in Hospitals enhances treatment outcomes and supports the burgeoning recognition of thyroid issues in broader healthcare discussions.

Get more detailed insights about UK Thyroid Disorder Market
Request Free Sample

Key Players and Competitive Insights

The thyroid disorder market exhibits a competitive landscape characterized by a blend of innovation, strategic partnerships, and regional expansion. Key players such as AbbVie (US), Eli Lilly and Company (US), and Novartis (CH) are actively shaping the market dynamics. AbbVie (US) focuses on enhancing its product portfolio through strategic acquisitions and collaborations, which appears to bolster its market presence. Eli Lilly and Company (US) emphasizes innovation in drug development, particularly in biologics, which may provide a competitive edge in addressing unmet medical needs. Novartis (CH) is leveraging its global reach to expand its therapeutic offerings, indicating a strategy aimed at capturing a larger market share. Collectively, these strategies contribute to a moderately fragmented market structure, where competition is driven by both product differentiation and strategic positioning.In terms of business tactics, companies are increasingly localizing manufacturing and optimizing supply chains to enhance operational efficiency. This approach not only reduces costs but also improves responsiveness to market demands. The competitive structure of the thyroid disorder market is moderately fragmented, with several key players exerting influence. The collective actions of these companies suggest a trend towards consolidation, as they seek to enhance their competitive positioning through mergers and acquisitions.

In October AbbVie (US) announced a strategic partnership with a leading biotechnology firm to co-develop a novel thyroid hormone replacement therapy. This collaboration is significant as it may accelerate the development timeline and enhance the therapeutic options available for patients suffering from thyroid disorders. The partnership underscores AbbVie's commitment to innovation and its strategic focus on addressing the needs of this patient population.

In September Eli Lilly and Company (US) launched a new digital health platform aimed at improving patient engagement and adherence to thyroid disorder treatments. This initiative is noteworthy as it reflects the growing trend of integrating technology into healthcare, potentially leading to better patient outcomes and increased market share for Eli Lilly. The platform may also serve as a valuable tool for healthcare providers, enhancing their ability to monitor patient progress.

In August Novartis (CH) expanded its manufacturing capabilities in the UK to support the production of its thyroid disorder therapies. This expansion is indicative of Novartis's long-term commitment to the region and its strategy to ensure a reliable supply chain. By increasing local production, Novartis may mitigate risks associated with global supply chain disruptions, thereby enhancing its competitive advantage.

As of November current trends in the thyroid disorder market are increasingly defined by digitalization, sustainability, and the integration of artificial intelligence (AI) in drug development. Strategic alliances are becoming more prevalent, as companies recognize the value of collaboration in fostering innovation. The competitive landscape is shifting from traditional price-based competition to a focus on technological advancements and supply chain reliability. This evolution suggests that future differentiation will hinge on the ability to innovate and adapt to changing market dynamics.

Key Companies in the UK Thyroid Disorder Market include

Industry Developments

In recent months, the UK Thyroid Disorder Market has experienced significant developments. GlaxoSmithKline has continued to enhance its offerings in thyroid health, particularly through advancements in patient management solutions. Additionally, Eli Lilly announced expansion plans for its thyroid medication portfolio, focusing on improving access and patient education in the UK.

The market valuation of companies like Takeda Pharmaceutical and Amgen has seen a positive trend, driven by increased awareness and education surrounding thyroid disorders, resulting in enhanced patient engagement and treatment uptake. As for mergers and acquisitions, no notable public transactions have been reported recently concerning the leading companies in this space, such as Roche or BristolMyers Squibb, keeping the market relatively stable.

Over the past two to three years, legislative actions and healthcare funding reforms have positively influenced the availability of thyroid disorder treatments in the UK, with a marked increase in funding towards public health initiatives related to thyroid health in early 2022. This ongoing evolution reflects a collective effort among key players including Merck and Co, Novartis, and AbbVie to address the growing patient needs within the UK.

Future Outlook

UK Thyroid Disorder Market Future Outlook

The Thyroid Disorder Market is projected to grow at a 4.24% CAGR from 2025 to 2035, driven by increasing prevalence, advancements in diagnostics, and enhanced treatment options.

New opportunities lie in:

  • Development of telehealth platforms for remote patient monitoring
  • Investment in AI-driven diagnostic tools for early detection
  • Expansion of personalized medicine approaches for tailored therapies

By 2035, the thyroid disorder market is expected to achieve substantial growth and innovation.

Market Segmentation

UK Thyroid Disorder Market Type Outlook

  • Hypothyroidism
  • Hyperthyroidism

UK Thyroid Disorder Market End-User Outlook

  • Clinics
  • Hospitals
  • Others

UK Thyroid Disorder Market Treatment Outlook

  • Medications
  • Surgery
  • Radioactive iodine therapy

UK Thyroid Disorder Market Route of Administration Outlook

  • Intravenous
  • Oral
  • Other

Report Scope

MARKET SIZE 2024 156.95(USD Million)
MARKET SIZE 2025 163.6(USD Million)
MARKET SIZE 2035 247.92(USD Million)
COMPOUND ANNUAL GROWTH RATE (CAGR) 4.24% (2025 - 2035)
REPORT COVERAGE Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
BASE YEAR 2024
Market Forecast Period 2025 - 2035
Historical Data 2019 - 2024
Market Forecast Units USD Million
Key Companies Profiled AbbVie (US), Bristol-Myers Squibb (US), Eli Lilly and Company (US), Merck & Co. (US), Novartis (CH), Pfizer (US), Sanofi (FR), Takeda Pharmaceutical Company (JP), Amgen (US)
Segments Covered Type, Treatment, Route of Administration, End-User
Key Market Opportunities Advancements in personalized medicine enhance treatment options in the thyroid disorder market.
Key Market Dynamics Rising prevalence of thyroid disorders drives demand for innovative treatment options and enhanced patient management solutions.
Countries Covered UK
Author
Author
Author Profile
Satyendra Maurya LinkedIn
Research Analyst
An accomplished research analyst with high proficiency in market forecasting, data visualization, competitive benchmarking, and others. He holds a pronounced track record in research and consulting projects for sectors such as life sciences, medical devices, and healthcare IT. His capabilities in qualitative and quantitative analysis have resulted in positive client outcomes. Working on niche market trends, opportunities, sales, and forecasted value is part of his skill set.
Co-Author
Co-Author Profile
Garvit Vyas LinkedIn
Vice President - Operations
Garvit Vyas is a Research Analyst with experience in working across multiple industry domains in the market research sector. Over the past four years, he has been actively involved in analyzing diverse markets, gathering industry insights, and contributing to the development of comprehensive research reports. His work includes studying market trends, evaluating competitive landscapes, and supporting data-driven business insights. In the early phase of his career, Garvit worked on cross-domain research projects, which helped him build a strong foundation in market analysis, data interpretation, and industry intelligence across various sectors. Later, he transitioned into the Quality Control (QC) function, where he focuses on reviewing and refining research reports and marketing collaterals to ensure accuracy, consistency, and high editorial standards. His responsibilities include validating research data, improving report structure, and maintaining the overall quality of published content. Garvit is committed to maintaining strong research integrity and delivering reliable insights that support informed business decision-making.
Get In Touch
Leave a Comment

FAQs

What was the overall market valuation of the UK thyroid disorder market in 2024?

<p>The overall market valuation was $156.95 Million in 2024.</p>

What is the projected market valuation for the UK thyroid disorder market by 2035?

<p>The projected valuation for 2035 is $247.92 Million.</p>

What is the expected CAGR for the UK thyroid disorder market during the forecast period 2025 - 2035?

<p>The expected CAGR during the forecast period 2025 - 2035 is 4.24%.</p>

Which companies are considered key players in the UK thyroid disorder market?

<p>Key players include AbbVie, Bristol-Myers Squibb, Eli Lilly and Company, Merck & Co., Novartis, Pfizer, Sanofi, Takeda Pharmaceutical Company, and Amgen.</p>

What were the segment valuations for hypothyroidism and hyperthyroidism in 2024?

<p>In 2024, the valuation for hypothyroidism was $100.0 Million to $160.0 Million, while hyperthyroidism ranged from $56.95 Million to $87.92 Million.</p>

What treatment options are available in the UK thyroid disorder market and their valuations?

<p>Treatment options include medications valued at $70.0 Million to $110.0 Million, surgery at $40.0 Million to $60.0 Million, and radioactive iodine therapy at $46.95 Million to $77.92 Million.</p>

What routes of administration are utilized in the UK thyroid disorder market?

<p>Routes of administration include intravenous at $20.0 Million to $30.0 Million, oral at $100.0 Million to $160.0 Million, and other methods at $36.95 Million to $57.92 Million.</p>

What are the end-user segments in the UK thyroid disorder market?

<p>End-user segments include clinics valued at $30.0 Million to $48.0 Million, hospitals at $90.0 Million to $140.0 Million, and others at $36.95 Million to $59.92 Million.</p>

How does the market for medications compare to other treatment options in 2024?

<p>In 2024, the market for medications was valued between $70.0 Million and $110.0 Million, indicating a strong preference compared to surgery and radioactive iodine therapy.</p>

What trends are anticipated for the UK thyroid disorder market in the coming years?

<p>The market is likely to experience growth, with a projected valuation increase to $247.92 Million by 2035, driven by an expected CAGR of 4.24%.</p>

Download Free Sample

Kindly complete the form below to receive a free sample of this Report

No regional reports available for this market.

No country-specific reports available for this market.

Customer Stories
Case Study Cover Image
Case Study
Aerospace & Defense
Future of Dismounted Soldier Systems Market Trends & Adoption Roadmap 2019–2035

Compare Licence

×
Features License Type
Single User Multiuser License Enterprise User
Price $4,950 $5,950 $7,250
Maximum User Access Limit 1 User Upto 10 Users Unrestricted Access Throughout the Organization
Free Customization ✓ ✓ ✓
Direct Access to Analyst ✓ ✓ ✓
Deliverable Format ✓ ✓ ✓
Platform Access ✗ ✗ ✓
Discount on Next Purchase 10% 15% 15%
Printable Versions ✗ ✗ ✓